Incidental Screening Has No Impact on Adrenocortical CA

Tuesday, August 23, 2011 (Last Updated: 08/24/2011)

TUESDAY, Aug. 23 (HealthDay News) -- Detection rates and clinical outcomes in adrenocortical carcinoma (ACC) show no improvement due to incidental screening resulting from scans done for other purposes, according to a study published in the September issue of The Journal of Urology.

Alexander Kutikov, M.D., from the Fox Chase Cancer Center in Philadelphia, and colleagues investigated whether incidental screening performed for other purpose leads to earlier diagnosis or better clinical outcomes in ACC. Data from the National Cancer Database were used to form the study cohort of 4,275 patients diagnosed with ACC from 1985 to 2007. The Cochran-Armitage chi-square test was used to evaluate trends in the distribution of grouped tumor sizes, and all cases diagnosed through 2002 were assessed for calculation of relative five-year survival rates.

The investigators found that median survival in the patient cohort was 24 months. A total of 43.9 percent of the patients had localized ACC, and no stage migration occurred over time. In patients who underwent surgery for localized carcinoma, no statistical trends were observed for changes in tumor size. The five-year survival rates showed no significant improvement.

"Incidental screening resulting from scans done for other purposes is not associated with earlier detection or better outcomes in patients with ACC," the authors write.

Full Text (subscription or payment may be required)

Specialties Hematology & Oncology
Internal Medicine

Copyright © 2011 HealthDay. All rights reserved.


Vegetarian Entree: Spaghetti Squash Primavera
by OncoLink Editorial Team
April 16, 2013

7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015